Invasive pneumococcal disease (IPD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Invasive pneumococcal disease is defined as an infection confirmed by the isolation of Streptococcus pneumoniae from a normally sterile site (e.g., blood, cerebrospinal fluid, and pleural, joint, or peritoneal fluid but not sputum). Children with pneumococcal infection often present with non-specific symptoms and signs, including isolated fever. Specific populations of children are at increased risk of IPD. Children at exceptionally high risk are those with antibody deficiencies, such as X-linked (Bruton's) agammaglobulinemia, anatomic or functional asplenia, sickle cell disease, HIV infection, and those with cochlear implants or CSF leak. Children with other chronic illnesses (e.g., cardiac, pulmonary, or renal disease and diabetes mellitus) and those receiving chemotherapy or steroids are also at risk. Children in daycare from an early age also have a higher incidence of IPD. Around 10–20% of children with pneumococcal meningitis have underlying comorbidity. The manifestations of IPD are; Bacteremia, Pneumonia, Meningitis, Cellulitis, Sinusitis, Septic arthritis, Peritonitis, Otitis media, and Others. Bacteremia and pneumonia were most common, and the pneumonia patients by definition were bacteremic. Otherwise, meningitis was the most common manifestation of IPD (4.9%), while endocarditis/pericarditis was the least common (<1%).

 

The incidence of invasive pneumococcal disease in any population is affected by geographic location, time of year, serotype prevalence, age, comorbidities, and vaccination status. The highest incidence of the invasive pneumococcal disease occurs in adults ≥65 years of age, in children <2 years of age, and those with certain underlying conditions, such as HIV infection.

The incidence of invasive pneumococcal disease in individuals ≥65 years of age was 36.4 cases per 100,000 population. In infants <1 year, the incidence was 34.2 cases per 100,000 population, compared with 3.8 cases per 100,000 population in individuals between 18 and 34 years of age.

 

The competitive landscape of Invasive pneumococcal disease (IPD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Invasive pneumococcal disease (IPD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Invasive pneumococcal disease (IPD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Invasive pneumococcal disease (IPD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          13-valent pneumococcal conjugate vaccine         Wyeth   Phase 3

2          GSK1024850A  GlaxoSmithKline            Phase 3

3          VAXNEUVANCE™        Merck Sharp & Dohme Corp.     Phase 2/3